Case report: Improvement in refractory functional seizures, depression, and quality of life with ketamine-assisted therapy
- PMID: 37378010
- PMCID: PMC10291615
- DOI: 10.3389/fnins.2023.1197409
Case report: Improvement in refractory functional seizures, depression, and quality of life with ketamine-assisted therapy
Abstract
Functional seizures, a primary subtype of functional neurological disorder (FND), are a known cause of serious neurological disability with an increasing awareness of their impact amongst the neuroscience community. Situated at the intersection of neurology and psychiatry, FND is characterized by a range of alterations in motor, sensory or cognitive performance, such as abnormal movements, limb weakness, and dissociative, seizure-like episodes. Functional seizures are known, in part, to have psychological underpinnings; however, the lack of effective and consistent treatment options requires research and novel approaches to better understand the etiology, diagnosis and what constitutes a successful intervention. Ketamine, a selective blocker of the N-methyl-D-aspartate receptor, has a well-established safety and efficacy profile. In recent years, ketamine-assisted therapy has shown increasing potential for treating a broad range of psychiatric conditions, building on its demonstrated rapid-acting antidepressant effects. Here we present a 51-year-old female with refractory daily functional seizures leading to significant disability and a medical history significant for major depressive disorder (MDD) and posttraumatic stress disorder (PTSD). After unsuccessful treatment attempts, the patient underwent a novel protocol with ketamine-assisted therapy. After 3 weeks of ketamine-assisted therapy followed by 20 weeks of intermittent ketamine treatment and ongoing integrative psychotherapy, the patient's seizures were significantly reduced in frequency and severity. She experienced significant improvements in depressive symptoms and functional ability scores. To our knowledge, this is the first reported case describing improvement in functional seizures following ketamine-assisted therapy. While rigorous studies are needed, this case report encourages further investigation of ketamine-assisted therapy for functional seizures and other functional neurological symptoms.
Keywords: functional neurological disorder; functional seizures; ketamine-assisted therapy; mental health; quality of life.
Copyright © 2023 Argento, Omene, Jaeger, Kertes, Mitchell, Necyk, Thielking and Lewis.
Conflict of interest statement
EA was a part-time consultant to Numinus Wellness Inc. and AJ, AK, KM, PT, CN, and EL were employed by the company Numinus Wellness Inc. The remaining author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures
![Figure 1](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/10291615/bin/fnins-17-1197409-g001.gif)
![Figure 2](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/10291615/bin/fnins-17-1197409-g002.gif)
![Figure 3](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/10291615/bin/fnins-17-1197409-g003.gif)
Similar articles
-
Improvement in depressive symptoms in a patient with severe and enduring anorexia nervosa and comorbid major depressive disorder using psychotherapy-assisted IV ketamine : a case report.J Eat Disord. 2024 Jun 12;12(1):79. doi: 10.1186/s40337-024-01039-3. J Eat Disord. 2024. PMID: 38867336 Free PMC article.
-
Letter to the Editor: Depression As The First Symptom Of Frontal Lobe Grade 2 Malignant Glioma.Turk Psikiyatri Derg. 2022 Summer;33(2):143-145. doi: 10.5080/u25957. Turk Psikiyatri Derg. 2022. PMID: 35730515 English, Turkish.
-
Cognitive behavioural therapy for adults with dissociative seizures (CODES): a pragmatic, multicentre, randomised controlled trial.Lancet Psychiatry. 2020 Jun;7(6):491-505. doi: 10.1016/S2215-0366(20)30128-0. Epub 2020 May 20. Lancet Psychiatry. 2020. PMID: 32445688 Free PMC article. Clinical Trial.
-
The safety and efficacy of ketamine NMDA receptor blocker as a therapeutic intervention for PTSD review of a randomized clinical trial.Behav Brain Res. 2022 Apr 29;424:113804. doi: 10.1016/j.bbr.2022.113804. Epub 2022 Feb 16. Behav Brain Res. 2022. PMID: 35181391 Review.
-
Ketamine and its metabolites: Potential as novel treatments for depression.Neuropharmacology. 2023 Jan 1;222:109305. doi: 10.1016/j.neuropharm.2022.109305. Epub 2022 Oct 30. Neuropharmacology. 2023. PMID: 36354092 Review.
Cited by
-
Exploring psychedelic-assisted therapy in the treatment of functional seizures: A review of underlying mechanisms and associated brain networks.J Psychopharmacol. 2024 May;38(5):407-416. doi: 10.1177/02698811241248395. Epub 2024 Apr 23. J Psychopharmacol. 2024. PMID: 38654554 Free PMC article. Review.
-
Psychedelics, epilepsy, and seizures: a review.Front Pharmacol. 2024 Jan 12;14:1326815. doi: 10.3389/fphar.2023.1326815. eCollection 2023. Front Pharmacol. 2024. PMID: 38283836 Free PMC article. Review.
References
-
- Albott C. S., Lim K. O., Forbes M. K., Erbes C., Tye S. J., Grabowski J. G., et al. . (2018). Efficacy, safety, and durability of repeated ketamine infusions for comorbid posttraumatic stress disorder and treatment-resistant depression. J. Clin. Psychiatry 79:17m11634. doi: 10.4088/JCP.17m11634, PMID: - DOI - PubMed
Publication types
LinkOut - more resources
Full Text Sources